Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650858 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial on Treatment of Intraventricular Hemorrhage
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT00650858: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00650858 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00650858, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The specific objective of this trial is to determine the lowest dose and dose frequency possible with the best pharmacokinetic and safety profile and it's ability to remove a blood clot from the ventricular system.
Interventions
- DRUG tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2004-02 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650858
The ClinicalTrials.gov registry entry for NCT00650858 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo) is the first listed.
NCT00650858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00650858 about?
NCT00650858 is a clinical study titled "Clinical Trial on Treatment of Intraventricular Hemorrhage". The specific objective of this trial is to determine the lowest dose and dose frequency possible with the best pharmacokinetic and safety profile and it's ability to remove a blood clot from the ventricular system.
What is the current status of trial NCT00650858?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2004-02. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00650858?
The interventions under investigation include: tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo) (DRUG).
Who is sponsoring clinical trial NCT00650858?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.